Bibliografie Med Vol 163. pp 1730–1754, 2001
12. Niederman MS. 1994. Pathogenesis of airway colonization: lessons learned from studies of bacterial adherence. Eur Respir J 1994;7: 1737–1740.
13. Ruiz M, Ewig S, Marcos MA, Martinez JA, Arancibia F, Mensa J, Torres A. Etiology of community-acquired pneumonia: impact of age, comorbidity, and severity. Am J Respir Crit Care Med 1999;160: 397–405.
14. Feldman C, Ross S, Mahomed AG, Omar J, Smith C. The aetiology of severe community-acquired pneumonia and its impact on initial, empiric, antimicrobial chemotherapy. Respir Med 1995;89:187–192.
15. Dahmash NS, Chowdhury MNH. Re-evaluation of pneumonia re- quiring admission to an intensive care unit: a prospective study. Tho- rax 1994;49:71–76.
16. Leroy O, Santre C, Beuscart C. A 5-year study of severe community- acquired pneumonia with emphasis on prognosis in patients admit- ted to an ICU. Intensive Care Med 1995;21:24–31.
17. Moine P, Vercken JB, Chevret S, Chastang C, Gajdos P. Severe com- munity- acquired pneumonia: etiology, epidemiology, and prognosis factors. Chest 1994;105:1487–1495.
18. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low- risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243–250.
19. Neill AM, Martin IR, Weir R, et al. Community-acquired pneumo- nia: aetiology and usefulness of severity criteria on admission. Tho- rax 1996; 51: 1010–1016.
20. Lim WS, Lewis S, Macfarlane JT. Severity prediction rules in com- munity-acquired pneumonia: a validation study. Thorax 2000; 55: 219–223.
21. Lim WS, Macfarlane JT, Boswell TC, et al. Study of community-ac- quired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines. Thorax 2001; 56: 296–301.
22. ERS Task Force in Collaboration with ESCMID: M. Woodhead, F. Blasi, S. Ewig, G. Huchon, M. Ieven, A. Ortqvist,T. Schaberg*, A. Tor- res, G. van der Heijden and T.J.M. Verheij Guidelines for the manage- ment of adult lower respiratory tract infections, Eur Respir J 2005; 26: 1138–1180
23. Smith RP, Lipworth BJ, Cree IA, Spiers EM, Winter JH. Creactive protein. A clinical marker in communityacquired pneumonia. Chest 1995; 108: 1288–1291.
24. Hedlund J, Hansson LO. Procalcitonin and C-reactive protein levels in community-acquired pneumonia: correlation with etiology and prognosis. Infection 2000; 28: 68–73.
25. Marston BJ, Plouffe JF, File TM Jr, et al. Incidence of community- acquired pneumonia requiring hospitalization. Results of a popula- tion-based active surveillance Study in Ohio. The Community-Based Pneumonia Incidence Study Group. Arch Intern Med 1997; 157: 1709–1718.
26. Bishara J, Leibovici L, Ashkenazi S, Samra Z, Pitlik S. Seven-year study of bacteraemic pneumonia in a single institution. Eur J Clin Microbiol Infect Dis 2000; 19: 926–931.
27. Skerrett SJ. Diagnostic testing for community-acquired pneumonia. Clin Chest Med 1999; 20: 531–548.
28. Scott JA, Hall AJ. The value and complications of percutaneous tr- ansthoracic lung aspiration for the etiologic diagnosis of communi- ty-acquired pneumonia. Chest 1999; 116: 1716–1732.
29. Torres A, El Ebiary M. Bronchoscopic BAL in the diagnosis of ventilator-associated pneumonia. Chest 2000; 117: Suppl. 2, 198S–202S.
30. Reed WW, Byrd GS, Gates RH Jr, Howard RS, Weaver MJ. Sputum gram’s stain in community-acquired pneumococcal pneumonia. A meta-analysis. West J Med 1996; 165: 197–204.
31. Murdoch DR, Laing RT, Mills GD, et al. Evaluation of a rapid im- nr. 20 • 4/2009
munochromatographic test for detection of Streptococcus pneumo- niae antigen in urine samples from adults with community-acquired pneumonia. J Clin Microbiol 2001; 39: 3495–3498.
32. Burel E, Dufour P, Gauduchon V, Jarraud S, Etienne J. Evaluation of a rapid immunochromatographic assay for detection of Streptococcus pneumoniae antigen in urine samples. Eur J Clin Microbiol Infect Dis 2001; 20: 840–841.
33. Yzerman EP, den Boer JW, Lettinga KD, Schellekens J, Dankert J, Peeters M. Sensitivity of three urinary antigen tests associated with clinical severity in a large outbreak of Legionnaires’ disease in The Netherlands. J Clin Microbiol 2002; 40: 3232–3236.
34. Vikerfors T, Brodin G, Grandien M, Hirschberg L, Krook A, Petters- son CA. Detection of specific IgM antibodies for the diagnosis of Mycoplasma pneumoniae infections: a clinical evaluation. Scand J Infect Dis 1988; 20: 601–610.
35. Ramirez JA, Ahkee S, Tolentino A, Miller RD, Summersgill JT. Diag- nosis of Legionella pneumophila, Mycoplasma pneumoniae, or Chla- mydia pneumoniae lower respiratory infection using the polymerase chain reaction on a single throat swab specimen. Diagn Microbiol Infect Dis 1996; 24: 7–14.
36. Simpson JC, Macfarlane JT, Watson J, Woodhead MA. A national confidential enquiry into community-acquired pneumonia deaths in young adults in England and Wales. British Thoracic Society Re- search Committee and Public Health Laboratory Service. Thorax 2000; 55: 1040–1045.
37. Leroy O, Santre C, Beuscart C, et al. A five-year study of severe community-acquired pneumonia with emphasis on prognosis in pa- tients admitted to an intensive care unit. Intensive Care Med 1995; 21: 24–31.
38. Infectious Diseases Society of America/American Thoracic So- ciety Consensus Guidelines on the Management of Community- Acquired pneumonia in Adults: Lionel A. Mandell,Richard G. Wunderink, Antonio Anzueto,John G. Bartlett, 7G. Douglas Campbell,Nathan C. Dean,Scott F. Dowell,Thomas M. File, Jr. Dan- iel M. Musher,Michael S. Niederman,Antonio Torres, and Cynthia G. Whitney , Clinical Infectious Diseases 2007; 44:S27–72
39. Dunbar LM,Wunderink RG, HabibMP, et al.High-dose, short- course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis 2003; 37:752–60.
40. Rizzato G, Montemurro L, Fraioli P, et al. Efficacy of a three day course of azithromycin in moderately severe community- acquired pneumonia. Eur Respir J 1995; 8:398–402.
41. Tellier G, Niederman MS, Nusrat R, Patel M, Lavin B. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia. J Antimicrob Chemother 2004; 54:515–23.
42. Chastre J, Wolff M, Fagon JY, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003; 290:2588–98.
43. Ramirez JA, Srinath L, Ahkee S, Huang A, Raff MJ. Early switch from intravenous to oral cephalosporins in the treatment of hos- pitalized patients with community-acquired pneumonia. Arch Intern Med 1995; 155:1273–6.
44. Castro-Guardiola A, Viejo-Rodriguez AL, Soler-Simon S, et al. Efficacy and safety of oral and early-switch therapy for communi- ty-acquired pneumonia: a randomized controlled trial. Am J Med 2001; 111: 367–74.
45. Halm EA, Fine MJ, Kapoor WN, Singer DE, Marrie TJ, Siu AL. Instability on hospital discharge and the risk of adverse out- comes in patients with pneumonia. Arch Intern Med 2002; 162: 1278–1284.
| Page 2
| Page 3
| Page 4
| Page 5
| Page 6
| Page 7
| Page 8
| Page 9
| Page 10
| Page 11
| Page 12
| Page 13
| Page 14
| Page 15
| Page 16
| Page 17
| Page 18
| Page 19
| Page 20
| Page 21
| Page 22
| Page 23
| Page 24
| Page 25
| Page 26
| Page 27
| Page 28
| Page 29
| Page 30
| Page 31
| Page 32
| Page 33
| Page 34
| Page 35
| Page 36
| Page 37
| Page 38
| Page 39
| Page 40
| Page 41
| Page 42
| Page 43
| Page 44
| Page 45
| Page 46
| Page 47
| Page 48
| Page 49
| Page 50
| Page 51
| Page 52